Infections in patients diagnosed with multiple sclerosis: A multi-database study

Persson, Rebecca; Lee, S.; Yood, Marianne Ulcickas; Wagner, Capt M.; Minton, Neil; Niemcryk, Steve J.; Lindholm, Anders; Evans, Amber; Jick, Susan S.

doi:10.1016/j.msard.2020.101982

Cited by 71 publications

(95 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A multi-data-based study conducted in the Unites States showed patients with multiple sclerosis (MS) had a higher incidence of contracting infections compared to non-MS people. 127 The crude rate of infections was higher in those taking interferon-beta and glatiramer acetate, and still higher in those taking fingolimod, natalizumab or rituximab. 127 Consequently, COVID-19 infection was diagnosed in an MS patient under treatment with fingolimod in May 2020 from Iran.…”

Section: Neurological Comorbidities and Living Through The Pandemicmentioning

confidence: 96%

“…127 The crude rate of infections was higher in those taking interferon-beta and glatiramer acetate, and still higher in those taking fingolimod, natalizumab or rituximab. 127 Consequently, COVID-19 infection was diagnosed in an MS patient under treatment with fingolimod in May 2020 from Iran. 128 Severity of the underlying illness also contributes to this accentuated risk.…”

Section: Neurological Comorbidities and Living Through The Pandemicmentioning

confidence: 96%

See 1 more Smart Citation

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic

Roy

Ghosh

Dubey

et al. 2020

Can. J. Neurol. Sci.

170

186

View full text Add to dashboard Cite

Background: Albeit primarily a disease of respiratory tract, the 2019 coronavirus infectious disease (COVID-19) has been found to have causal association with a plethora of neurological, neuropsychiatric and psychological effects. This review aims to analyze them with a discussion of evolving therapeutic recommendations. Methods: PubMed and Google Scholar were searched from 1 January 2020 to 30 May 2020 with the following key terms: “COVID-19”, “SARS-CoV-2”, “pandemic”, “neuro-COVID”, “stroke-COVID”, “epilepsy-COVID”, “COVID-encephalopathy”, “SARS-CoV-2-encephalitis”, “SARS-CoV-2-rhabdomyolysis”, “COVID-demyelinating disease”, “neurological manifestations”, “psychosocial manifestations”, “treatment recommendations”, “COVID-19 and therapeutic changes”, “psychiatry”, “marginalised”, “telemedicine”, “mental health”, “quarantine”, “infodemic” and “social media”. A few newspaper reports related to COVID-19 and psychosocial impacts have also been added as per context. Results: Neurological and neuropsychiatric manifestations of COVID-19 are abundant. Clinical features of both central and peripheral nervous system involvement are evident. These have been categorically analyzed briefly with literature support. Most of the psychological effects are secondary to pandemic-associated regulatory, socioeconomic and psychosocial changes. Conclusion: Neurological and neuropsychiatric manifestations of this disease are only beginning to unravel. This demands a wide index of suspicion for prompt diagnosis of SARS-CoV-2 to prevent further complications and mortality.

show abstract

Section: Neurological Comorbidities and Living Through The Pandemicmentioning

confidence: 96%

Section: Neurological Comorbidities and Living Through The Pandemicmentioning

confidence: 96%

Neurological and Neuropsychiatric Impacts of COVID-19 Pandemic

Roy

Ghosh

Dubey

et al. 2020

Can. J. Neurol. Sci.

170

186

View full text Add to dashboard Cite

show abstract

“…In a recent month’s journal club, Willis MD et al considered three papers relevant to answer these questions [ 58 ]. The first study aimed to characterize the infection risk of patients with MS compared with a cohort of patients without MS, using two large databases with a long follow-up time [ 58 , 59 ]. According with the results, MS patients were demonstrated to be at an increased risk generally of infections, and of infections requiring hospitalization.…”

Section: Covid-19 and Neuroimmunological Disordersmentioning

confidence: 99%

COVID-19 and neurological disorders: are neurodegenerative or neuroimmunological diseases more vulnerable?

2020

View full text Add to dashboard Cite

Neurological disorders and coronavirus 2019 (COVID-19) pandemic are two conditions with a recent well-documented association. Intriguing evidences showed that COVID-19 infection can modify clinical spectrum of manifested neurological disorders but also it plays a crucial role in the development of future diseases as long-tem consequences. In this viewpoint review, we aimed to assess the vulnerability to SARS-CoV-2 infection and development of COVID-19 among neurological disorders. With this in mind, we tested the hypothesis that age rather than neuropathology itself could be decisive in neurodegenerative diseases such as Parkinson's disease, whereas neuropathology rather than age may be critical in neuroimmunological diseases such as Multiple Sclerosis. Highlighting the role of potential susceptibility or protection factors from this disastrous infection, we also stratify the risk for future neurodegeneration.

show abstract

“…It is established that patients with MS have a higher risk of infections requiring hospitalization, pointing to a possible increase in viral infections, pneumonia and influenza. 2 Our results show that patients with MS have experienced a COVID-19 incidence that is more than double that of the general population and this cannot be attributed to having undergone more PCR studies.…”

Section: Discussionmentioning

confidence: 56%